Immunometabolism in cancer: basic mechanisms and new targeting strategy

• DOI: 10.1038/s41420-024-02006-2
• Publication Date: 2024-05-16T14:02:19Z
• Authors: Ranran Su; Yingying Shao; Manru Huang; Donghui Liu; Haiyang Yu; Yuling Qiu
• Keywords: 0301 basic medicine; 0303 health sciences; QH573-671; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Review Article; Cytology; RC254-282

AbstractMaturing immunometabolic research empowers immune regulation novel approaches. Progressive metabolic adaptation of tumor cells permits a thriving tumor microenvironment (TME) in which immune cells always lose the initial killing capacity, which remains an unsolved dilemma even with the development of immune checkpoint therapies. In recent years, many studies on tumor immunometabolism have been reported. The development of immunometabolism may facilitate anti-tumor immunotherapy from the recurrent crosstalk between metabolism and immunity. Here, we discuss clinical studies of the core signaling pathways of immunometabolism and their inhibitors or agonists, as well as the specific functions of these pathways in regulating immunity and metabolism, and discuss some of the identified immunometabolic checkpoints. Understanding the comprehensive advances in immunometabolism helps to revise the status quo of cancer treatment.